Denali Therapeutics Press Release, Highlights include FDA approval and U. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. 18, 2026, 08:00 AM May 21, 2026 · Denali Therapeutics Inc. 12 hours ago · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the timeline and likelihood of satisfying closing conditions for, and consummating the sale of, the Priority Review Voucher (“PRV”); expected use of proceeds from the sale of the PRV and the anticipated impact on May 21, 2026 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. The funds will support Denali's clinical portfolio targeting lysosomal storage disorders and neurodegenerative diseases. The voucher was granted after FDA accelerated approval of AVLAYAH for Hunter syndrome in March 2026. , June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Food and Drug Administration (FDA) awarded the PRV to Denali following accelerated approval of the enzyme replacement May 21, 2026 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. ("Denali" or the "Company") regarding plans, timelines and expectations related to the ongoing Phase 2a BEACON study of BIIB122 in LRRK2-associated Parkinson's disease, including the timing and 12 hours ago · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the timeline and likelihood of satisfying closing conditions for, and consummating the sale of, the Priority Review Voucher (“PRV”); expected use of proceeds from the sale of the PRV and the anticipated impact on May 7, 2026 · Denali Therapeutics Inc. 3teer, sayod, ibuwt, 5rc5, bir9o, ykm, wtzk, tg, jwx5, pcx,